RNAi Therapeutics and Technology Market Size, Share, Trends, Industry Analysis Report

List of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Market Segmentations
1.4. Key Questions Answered
1.5. Chapter Outlines

2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis

2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis

2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources

2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach

2.4.2.2. Advantages of Primary Research

2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions

2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers

2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity

2.4.3. Analytical Tools and Databases

2.5. Robust Quality Control

3. MARKET DYNAMICS
3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach

3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)

3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis

3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact

3.6. Limitations

4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates

4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations
4.2.2.3. Impact of Currency Fluctuations on the Industry

4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk

4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt

4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution

4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk

4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation

4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market

4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War

4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies

4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product (GDP)
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross-Border Dynamics

4.3. Conclusion

5. EXECUTIVE SUMMARY

6. INTRODUCTION
6.1. Chapter Overview
6.2. Key Milestones and Historical Trends
6.2.1. Discovery of RNAi
6.2.2. RNAi Therapy Development Efforts

6.3. Mechanism of RNAi
6.3.1. Components of RNAi
6.3.2. Cellular Mechanism

6.4. Types of RNAi Molecules
6.4.1. siRNA
6.4.2. miRNA
6.4.3. shRNA

6.5. RNAi Delivery Technologies and Vehicles
6.5.1. Lipid Nanoparticles
6.5.2. Conjugate Systems
6.5.3. Polymer-based Platforms
6.5.4. Next-Generation and Extra-Hepatic Delivery Vectors

6.6. Applications of RNAi
6.6.1. Functional Genomics
6.6.2. Therapeutics
6.6.3. Biotechnology
6.6.4. Genome-scale Screening

6.7. Advantages and Disadvantages of RNAi
6.7.1. Advantages of RNAi
6.7.2. Disadvantages of RNAi
6.7.3. Case Study: Concerns Discussed During Regulatory Submissions in Clinic

6.8. Future Perspectives

7. MARKET OVERVIEW
7.1. Chapter Overview
7.2. RNAi Therapeutics: Marketed and Development Pipeline
7.2.1. Analysis by Type of RNAi Molecule
7.2.2. Analysis by Phase of Development
7.2.3. Analysis by Type of Molecule and Phase of Development
7.2.4. Analysis by Target Gene
7.2.5. Analysis by Therapeutic Area
7.2.6. Analysis by Route of Administration
7.2.7. RNAi Therapeutics: Special Designations
7.2.8. Key Players

8. COMPETITIVE LANDSCAPE
8.1. Chapter Overview
8.2. RNAi Therapeutics: Developer Landscape
8.2.1. Analysis by Year of Establishment
8.2.2. Analysis by Company Size
8.2.3. Analysis by Location of Headquarters
8.2.4. Analysis by Location of Headquarters (Country)
8.2.5. Key Players: Analysis by Number of Drug Candidates

8.3. RNAi Therapeutics: Regional Landscape

9. COMPANY COMPETITIVENESS ANALYSIS
9.1. Chapter Overview
9.2. Assumptions / Key Parameters
9.3. Methodology
9.4. Company Competitive Analysis: RNAi Therapeutics Developers
9.5. Developers based in North America
9.6. Developers based in Europe
9.7. Developers based in Asia-Pacific

10. APPROVED AND LATE-STAGE RNAi THERAPEUTICS
10.1. Chapter Overview
10.2. Onpattro®
10.2.1. Drug Overview
10.2.2. Technology Overview
10.2.3. Current Development Status
10.2.4. Recent Clinical Trial Results
10.2.5. Recent Partnerships

10.3. Givlaari®
10.3.1. Drug Overview
10.3.2. Technology Overview
10.3.3. Current Development Status
10.3.4. Recent Clinical Trial Results
10.3.5. Recent Partnerships

10.4. Leqvio®
10.4.1. Drug Overview
10.4.2. Technology Overview
10.4.3. Current Development Status
10.4.4. Recent Clinical Trial Results
10.4.5. Recent Partnerships

10.5. Oxlumo™
10.5.1. Drug Overview
10.5.2. Technology Overview
10.5.3. Current Development Status
10.5.4. Recent Clinical Trial Results
10.5.5. Recent Partnerships

10.6. Qfitlia™
10.6.1. Drug Overview
10.6.2. Technology Overview
10.6.3. Current Development Status
10.6.4. Recent Clinical Trial Results

10.7. Amvuttra®
10.7.1. Drug Overview
10.7.2. Technology Overview
10.7.3. Current Development Status
10.7.4. Recent Clinical Trial Results

10.8. SYL 1001
10.8.1. Drug Overview
10.8.2. Technology Overview
10.8.3. Current Development Status
10.8.4. Recent Clinical Trial Results

10.9. Vigil-EWS
10.9.1. Drug Overview
10.9.2. Technology Overview
10.9.3. Current Development Status
10.9.4. Recent Clinical Trial Results

10.10. SR-061
10.10.1. Drug Overview
10.10.2. Technology Overview
10.10.3. Current Development Status

10.11. Rivfloza™
10.11.1. Drug Overview
10.11.2. Technology Overview
10.11.3. Current Development Status
10.11.4. Recent Clinical Trial Results

11. TECHNOLOGY PLATFORMS AND DELIVERY SYSTEMS
11.1. Chapter Overview
11.2. Components of RNAi Delivery Systems
11.2.1. RNAi Triggers
11.2.1.1. Asymmetric siRNA (cp-siRNA)
11.2.1.2. DNA Directed RNAi (ddRNAi)
11.2.1.3. Dicer Substrate siRNA (DsiRNA)
11.2.1.4. Naked siRNA
11.2.1.5. Self-Deliverable RNA (sd-RNA)
11.2.1.6. Self-Deliverable rxRNA (sd-rxRNA)
11.2.1.7. Unlocked Nucleobase Analog (UNA) Containing siRNA (UsiRNA)

11.2.2. Technology Platforms and Delivery Systems
11.2.2.1. Analysis by Purpose of Technology
11.2.2.2. Analysis by Type of Molecules Delivered
11.2.2.3. Analysis by Type of Cells / Tissues Targeted

11.2.3. Technology Platforms: List of Developers
11.2.3.1. Analysis by Year of Establishment
11.2.3.2. Analysis by Company Size
11.2.3.3. Analysis by Location of Headquarters (Region)
11.2.3.4. Analysis by Location of Headquarters (Country)

11.2.4. Technology Platform: Profiles
11.2.4.1. Conjugated Delivery Technologies
11.2.4.1.1. GalNAc Conjugate Delivery System, Alnylam Pharmaceuticals
11.2.4.1.1.1. Technology Overview
11.2.4.1.1.2. Pipeline Molecules in Development
11.2.4.1.1.3. Analyst’s Perspective

11.2.4.1.2. Protein Nanoparticle (PNP) Delivery Technology, Ariz Precision Medicine
11.2.4.1.2.1. Technology Overview
11.2.4.1.2.2. Pipeline Molecules in Development
11.2.4.1.2.3. Analyst’s Perspective

11.2.4.1.3. Targeted RNAi Molecule (TRiM) Platform, Arrowhead Pharmaceuticals
11.2.4.1.3.1. Technology Overview
11.2.4.1.3.2. Pipeline Molecules in Development
11.2.4.1.3.3. Analyst’s Perspective

11.2.4.2. Drug Discovery and Development Technologies

11.2.4.2.1. GalXC Conjugated RNAi Technology Platform, Dicerna Pharmaceuticals
11.2.4.2.1.1. Technology Overview
11.2.4.2.1.2. Pipeline Molecules in Development
11.2.4.2.1.3. Analyst’s Perspective

11.2.4.2.2. The Vigil Platform, Gradalis
11.2.4.2.2.1. Technology Overview
11.2.4.2.2.2. Pipeline Molecules in Development
11.2.4.2.2.3. Analyst’s Perspective

11.2.4.2.3. mRNAi GOLD Platform, Silence Therapeutics
11.2.4.2.3.1. Technology Overview
11.2.4.2.3.2. Pipeline Molecules in Development
11.2.4.2.3.3. Analyst’s Perspective

12. TECHNOLOGY COMPETITIVENESS ANALYSIS
12.1. Chapter Overview
12.2. Assumptions / Key Parameters
12.3. Methodology

12.4. Technology Competitiveness Analysis: RNAi Therapeutics Technologies
12.4.1. Technology Competitiveness Analysis: Drug Delivery Technologies
12.4.2. Technology Competitiveness Analysis: Drug Discovery / Development Technologies

13. KEY THERAPEUTIC INDICATIONS
13.1. Chapter Overview
13.2. Oncological Disorders
13.2.1. Analysis by Target Indication and Phase of Development
13.2.2. Analysis by Type of RNAi Molecule

13.3. Infectious Diseases
13.3.1. Analysis by Target Indication and Phase of Development
13.3.2. Analysis by Type of RNAi Molecule

13.4. Metabolic Disorders
13.4.1. Analysis by Target Indication and Phase of Development
13.4.2. Analysis by Type of RNAi Molecule

13.5. Ophthalmic Diseases
13.5.1. Analysis by Target Indication and Phase of Development
13.5.2. Analysis by Type of RNAi Molecule

13.6. Genetic Disorders
13.6.1. Analysis by Target Indication and Phase of Development
13.6.2. Analysis by Type of RNAi Molecule

14. CLINICAL TRIAL ANALYSIS
14.1. Chapter Overview
14.2. Scope and Methodology

14.3. RNAi Therapeutics: Clinical Trial Analysis
14.3.1. Analysis by Trial Registration Year
14.3.2. Analysis by Trial Phase
14.3.3. Analysis by Trial Recruitment Status
14.3.4. Analysis by Type of Sponsor / Collaborator
14.3.5. Analysis by Type of RNAi Molecule and Trial Recruitment Status
14.3.6. Analysis by Therapeutic Area
14.3.7. Geographical Analysis by Number of Clinical Trials
14.3.8. Geographical Analysis by Number of Clinical Trials, Trial Phase and Recruitment Status
14.3.9. Geographical Analysis by Number of Clinical Trials and Type of RNAi Molecule
14.3.10. Geographical Analysis by Number of Clinical Trials, Type of RNAi Molecule and Trial Phase
14.3.11. Geographical Analysis by Number of Clinical Trials and Therapeutic Area
14.3.12. Geographical Analysis by Number of Clinical Trials, Therapeutic Area and Trial Phase
14.3.13. Geographical Analysis of Enrolled Patient Population by Location of Trial
14.3.14. Geographical Analysis of Enrolled Patient Population by Trial Phase and Trial Recruitment Status
14.3.15. Geographical Analysis of Enrolled Patient Population by Type of RNAi Molecule and Location of Trial
14.3.16. Geographical Analysis of Enrolled Patient Population by Type of RNAi Molecule, Trial Phase and Location of Trial
14.3.17. Geographical Analysis of Enrolled Patient Population by Therapeutic Area and Location of Trial
14.3.18. Geographical Analysis of Enrolled Patient Population by Therapeutic Area, Trial Phase and Location of Trial

14.4. Concluding Remarks
14.4.1. Key Therapeutic Candidates
14.4.2. Key Clinical Trials

15. KEY OPINION LEADERS
15.1. Chapter Overview
15.2. RNAi Therapeutics: Key Opinion Leaders
15.2.1. Analysis by Type of Organization
15.2.2. Analysis by Qualification
15.2.3. Analysis by Geographical Location of KOLs
15.2.4. Most Prominent Organizations: Analysis by Number of KOLs
15.2.5. KOL Activeness v/s KOL Strength
15.2.6. Most Prominent KOLs: Analysis by KOL Strength
15.2.7. Most Prominent KOLs: Comparison of RA Score and Third-Party Score

16. PATENT ANALYSIS
16.1. Chapter Overview
16.2. Scope and Methodology

16.3. RNAi Therapeutics: Patent Analysis
16.3.1. Analysis by Publication Year
16.3.2. Analysis by Patent Type and Publication Year
16.3.3. Analysis by CPC Code
16.3.4. Analysis by Type of Applicant

16.3.5. Analysis by Geography
16.3.5.1. Analysis by Geography: North American Scenario
16.3.5.2. Analysis by Geography: European Scenario
16.3.5.3. Analysis by Geography: Asia-Pacific Scenario

16.3.6. Emerging Focus Areas
16.3.7. Leading Players: Analysis by Number of Patents

16.4. RNAi Therapeutics: Patent Benchmarking Analysis

16.4.1. Analysis by Key Patent Characteristics
16.4.1.1. Arrowhead Pharmaceuticals and Sirna Therapeutics
16.4.1.2. Other Leading Patent Assignees

16.5. RNAi Therapeutics: Patent Valuation Analysis

17. PUBLICATION ANALYSIS
17.1. Chapter Overview
17.2. Scope and Methodology
17.3. Analysis by Year of Publication
17.4. Analysis by Type of Publication
17.5. Most Popular Keywords
17.6. Most Popular Journals: Analysis by Number of Publications
17.7. Most Popular Publisher: Analysis by Number of Publications
17.8. Most Popular Copyright Holders: Analysis by Number of Publications
17.9. Key Funding Institutes: Analysis by Number of Publications

18. PARTNERSHIPS AND COLLABORATIONS
18.1. Chapter Overview
18.2. Partnership Models

18.3. RNAi Therapeutics: Recent Partnerships and Collaborations
18.3.1. Analysis by Year of Partnership
18.3.2. Analysis by Type of Partnership
18.3.3. Analysis by Type of RNAi Molecule
18.3.4. Analysis by Scale of Partnership
18.3.5. Analysis by Therapeutic Area
18.3.6. Most Active Players: Analysis by Number of Partnerships

18.3.7. Regional Analysis
18.3.7.1. Country Distribution
18.3.7.2. Intercontinental and Intracontinental Deals

19. FUNDING AND INVESTMENT ANALYSIS
19.1. Chapter Overview
19.2. Types of Funding

19.3. RNAi Therapeutics: Funding and Investment Analysis
19.3.1. Analysis by Cumulative Funding Instances, Since 2014
19.3.2. Analysis by Amount Invested
19.3.3. Analysis by Type of Funding
19.3.4. Analysis by Year and Type of Funding
19.3.5. Analysis of Amount Invested Across Different Types of RNAi Molecules
19.3.6. Regional Analysis by Amount Invested
19.3.7. Most Active Players
19.3.8. Key Investors

19.4. Concluding Remarks

20. KEY COMMERCIALIZATION STRATEGIES
20.1. Chapter Overview
20.2. Successful Drug Launch Strategy: ROOTS Framework
20.3. Successful Drug Launch Strategy: Product Differentiation
20.4. Commonly Adopted Commercialization Strategies based on Stage of Development of the Product
20.5. Approved RNAi Therapeutics

20.6. Key Commercialization Strategies Adopted by RNAi-based Therapy Developers
20.6.1. Strategies Adopted Before Therapy Approval
20.6.1.1. Participation in Global Events
20.6.1.1.1. Onpattro
20.6.1.1.2. Givlaari
20.6.1.1.3. Oxlumo

20.6.1.2. Collaboration with Stakeholders and Pharmaceutical Firms
20.6.1.2.1. Leqvio

20.6.1.3. Indication Expansion
20.6.1.3.1. Onpattro
20.6.1.3.2. Givlaari
20.6.1.3.3. Oxlumo
20.6.1.3.4. Leqvio

20.6.2. Strategies Adopted During / Post Therapy Approval
20.6.2.1. Participation in Global Events
20.6.2.1.1. Onpattro
20.6.2.1.2. Leqvio

20.6.2.2. Geographical Expansion
20.6.2.2.1. Onpattro
20.6.2.2.2. Givlaari
20.6.2.2.3. Oxlumo
20.6.2.2.4. Leqvio

20.6.2.3. Patient Assistance Programs
20.6.2.3.1. Onpattro
20.6.2.3.2. Givlaari
20.6.2.3.3. Oxlumo

20.6.2.4. Awareness Through Product Websites

20.6.2.5. Collaboration with Stakeholders and Pharmaceutical Firms
20.6.2.5.1. Onpattro
20.6.2.5.2. Givlaari
20.6.2.5.3. Oxlumo
20.6.2.5.4. Leqvio

20.6.2.6. Aligning with Government Initiatives to Ensure High Adoption Rate
20.6.2.6.1. Onpattro
20.6.2.6.2. Givlaari
20.6.2.6.3. Leqvio

20.7. Concluding Remarks

21. RNAi IN DIAGNOSTICS
21.1. Chapter Overview
21.2. Key Characteristics of Biomarkers
21.3. Circulating miRNA Biomarkers

21.4. miRNA Biomarkers in Oncological Disorders
21.4.1. Importance of Early Cancer Detection
21.4.2. Cancer Screening and Diagnosis

21.4.3. Conventional Cancer Diagnostics
21.4.3.1. Biopsy

21.4.4. Need for Non-Invasive Approaches

21.4.5. Key Indications
21.4.5.1. Breast Cancer
21.4.5.2. Colorectal Cancer
21.4.5.3. Gastric Cancer

21.4.5.4. Hematological Cancer
21.4.5.4.1. Acute Myeloid Leukemia
21.4.5.4.2. Lymphoma

21.4.5.5. Lung Cancer
21.4.5.6. Prostate Cancer

21.5. miRNA Biomarkers in Cardiovascular Diseases
21.5.1. Key Indications
21.5.1.1. Coronary Artery Disease
21.5.1.2. Myocardial Infarction

21.6. miRNA Based Diagnostic Tests

22. RNAi THERAPEUTICS SERVICE PROVIDERS
22.1. Chapter Overview
22.2. Analysis by Types of Service Providers

22.3. RNAi Therapeutics: List of CROs
22.3.1. Analysis by Year of Establishment
22.3.2. Analysis by Location of Headquarters
22.3.3. Analysis by Company Size
22.3.4. Analysis by Type of RNAi Molecule

22.4. RNAi Therapeutics: List of CMOs
22.4.1. Analysis by Year of Establishment
22.4.2. Analysis by Location of Headquarters
22.4.3. Analysis by Company Size
22.4.4. Analysis by Type of RNAi Molecule

22.5. RNAi Therapeutics: List of Consumables and Other Service Providers
22.5.1. Analysis by Year of Establishment
22.5.2. Analysis by Location of Headquarters
22.5.3. Analysis by Company Size
22.5.4. Analysis by Type of RNAi Molecule

23. DEMAND ANALYSIS
23.1. Chapter Overview
23.2. Methodology

23.3. Global Demand for RNAi Therapeutics, till 2035
23.3.1. Analysis by Therapeutic Approach
23.3.2. Analysis by Target Therapeutic Area
23.3.3. Analysis by Route of Administration
23.3.4. Analysis by Key Players
23.3.5. Analysis by Geography

24. GLOBAL RNAi THERAPEUTICS AND TECHNOLOGY MARKET
24.1. Chapter Overview
24.2. Key Assumptions and Methodology

24.3. Global RNAi Therapeutics and Technology Market, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
24.3.1. Scenario Analysis
24.3.1.1. Conservative Scenario
24.3.1.2. Optimistic Scenario

24.4. Key Market Segmentations

25. RNAi THERAPEUTICS AND TECHNOLOGY MARKET, BY TYPE OF RNAi MOLECULE
25.1. Chapter Overview
25.2. RNAi Therapeutics and Technology Market: Distribution by Type of RNAi Molecule
25.2.1. RNAi Therapeutics and Technology Market for siRNA, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
25.2.2. RNAi Therapeutics and Technology Market for miRNA, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
25.2.3. RNAi Therapeutics and Technology Market for shRNA, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
25.2.4. RNAi Therapeutics and Technology Market for Other RNAi Molecules, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

25.3. Data Triangulation and Validation

26. RNAi THERAPEUTICS AND TECHNOLOGY MARKET, BY DELIVERY TECHNOLOGY
26.1. Chapter Overview
26.2. RNAi Therapeutics and Technology Market: Distribution by Delivery Technology
26.2.1. RNAi Therapeutics and Technology Market for Lipid Nanoparticles, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
26.2.2. RNAi Therapeutics and Technology Market for Emerging Nanomaterials, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
26.2.3. RNAi Therapeutics and Technology Market for Polymer and Conjugate Systems, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
26.2.4. RNAi Therapeutics and Technology Market for Viral Vectors, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
26.2.5. RNAi Therapeutics and Technology Market for Other Delivery Technologies, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

26.3. Data Triangulation and Validation

27. RNAi THERAPEUTICS AND TECHNOLOGY MARKET, BY THERAPEUTIC AREA
27.1. Chapter Overview
27.2. RNAi Therapeutics and Technology Market: Distribution by Therapeutic Area
27.2.1. RNAi Therapeutics and Technology Market for Oncological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
27.2.2. RNAi Therapeutics and Technology Market for Genetic Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
27.2.3. RNAi Therapeutics and Technology Market for Metabolic Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
27.2.4. RNAi Therapeutics and Technology Market for Hematological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
27.2.5. RNAi Therapeutics and Technology Market for Ophthalmic Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
27.2.6. RNAi Therapeutics and Technology Market for Other Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

27.3. Data Triangulation and Validation

28. RNAi TECHNOLOGY MARKET, BY TYPE OF PAYMENT
28.1. Chapter Overview
28.2. RNAi Technology Market: Distribution by Type of Payment
28.2.1. RNAi Technology Market for Upfront Payments, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
28.2.2. RNAi Technology Market for Milestone Payments, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

28.3. Data Triangulation and Validation

29. RNAi THERAPEUTICS AND TECHNOLOGY MARKET, BY END USER
29.1. Chapter Overview
29.2. RNAi Therapeutics and Technology Market: Distribution by End User
29.2.1. RNAi Therapeutics and Technology Market for Pharmaceutical and Biotechnology Companies, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
29.2.2. RNAi Therapeutics and Technology Market for Academic and Research Institutes, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
29.2.3. RNAi Therapeutics and Technology Market for Contract Development and Manufacturing Organizations, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
29.2.4. RNAi Therapeutics and Technology Market for Diagnostic Laboratories, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
29.2.5. RNAi Therapeutics and Technology Market for Other End Users, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

29.3. Data Triangulation and Validation

30. RNAi THERAPEUTICS AND TECHNOLOGY MARKET, BY GEOGRAPHICAL REGIONS
30.1. Chapter Overview
30.2. RNAi Therapeutics and Technology Market: Distribution by Geographical Regions
30.2.1. RNAi Therapeutics and Technology Market in North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
30.2.2. RNAi Therapeutics and Technology Market in Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
30.2.3. RNAi Therapeutics and Technology Market in Asia-Pacific, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
30.2.4. RNAi Therapeutics and Technology Market in Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
30.2.5. RNAi Therapeutics and Technology Market in Middle East and North Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

30.3. Market Dynamics Assessment
30.3.1. Revenue Shift Analysis
30.3.2. Penetration Growth (P-G) Matrix

30.4. Data Triangulation and Validation

31. RNAi THERAPEUTICS MARKET: PRODUCT-WISE SALES FORECAST
31.1. RNAi Therapeutics Market: Product-Wise Sales Forecast

32. RNAi THERAPEUTICS AND TECHNOLOGY MARKET: NORTH AMERICA
32.1. RNAi Therapeutics and Technology Market in North America: Distribution by Type of RNAi Molecule
32.1.1. RNAi Therapeutics and Technology Market in North America for siRNA, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
32.1.2. RNAi Therapeutics and Technology Market in North America for miRNA, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
32.1.3. RNAi Therapeutics and Technology Market in North America for shRNA, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
32.1.4. RNAi Therapeutics and Technology Market in North America for Other RNAi Molecules, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

32.2. RNAi Therapeutics and Technology Market in North America: Distribution by Delivery Technology
32.2.1. RNAi Therapeutics and Technology Market in North America for Lipid Nanoparticles, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
32.2.2. RNAi Therapeutics and Technology Market in North America for Emerging Nanomaterials, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
32.2.3. RNAi Therapeutics and Technology Market in North America for Polymer and Conjugate Systems, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
32.2.4. RNAi Therapeutics and Technology Market in North America for Viral Vectors, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
32.2.5. RNAi Therapeutics and Technology Market in North America for Other Delivery Technologies, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

32.3. RNAi Therapeutics and Technology Market in North America: Distribution by Therapeutic Area
32.3.1. RNAi Therapeutics and Technology Market in North America for Oncological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
32.3.2. RNAi Therapeutics and Technology Market in North America for Genetic Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
32.3.3. RNAi Therapeutics and Technology Market in North America for Metabolic Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
32.3.4. RNAi Therapeutics and Technology Market in North America for Hematological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
32.3.5. RNAi Therapeutics and Technology Market in North America for Ophthalmic Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
32.3.6. RNAi Therapeutics and Technology Market in North America for Other Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

32.4. RNAi Technology Market in North America: Distribution by Type of Payment
32.4.1. RNAi Technology Market in North America for Upfront Payments, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
32.4.2. RNAi Technology Market in North America for Milestone Payments, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

32.5. RNAi Therapeutics and Technology Market in North America: Distribution by End User
32.5.1. RNAi Therapeutics and Technology Market in North America for Pharmaceutical and Biotechnology Companies, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
32.5.2. RNAi Therapeutics and Technology Market in North America for Academic and Research Institutes, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
32.5.3. RNAi Therapeutics and Technology Market in North America for Contract Development and Manufacturing Organizations, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
32.5.4. RNAi Therapeutics and Technology Market in North America for Diagnostic Laboratories, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
32.5.5. RNAi Therapeutics and Technology Market in North America for Other End Users, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

33. RNAi THERAPEUTICS AND TECHNOLOGY MARKET: EUROPE
33.1. RNAi Therapeutics and Technology Market in Europe: Distribution by Type of RNAi Molecule
33.1.1. RNAi Therapeutics and Technology Market in Europe for siRNA, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
33.1.2. RNAi Therapeutics and Technology Market in Europe for miRNA, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
33.1.3. RNAi Therapeutics and Technology Market in Europe for shRNA, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
33.1.4. RNAi Therapeutics and Technology Market in Europe for Other RNAi Molecules, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

33.2. RNAi Therapeutics and Technology Market in Europe: Distribution by Delivery Technology
33.2.1. RNAi Therapeutics and Technology Market in Europe for Lipid Nanoparticles, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
33.2.2. RNAi Therapeutics and Technology Market in Europe for Emerging Nanomaterials, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
33.2.3. RNAi Therapeutics and Technology Market in Europe for Polymer and Conjugate Systems, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
33.2.4. RNAi Therapeutics and Technology Market in Europe for Viral Vectors, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
33.2.5. RNAi Therapeutics and Technology Market in Europe for Other Delivery Technologies, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

33.3. RNAi Therapeutics and Technology Market in Europe: Distribution by Therapeutic Area
33.3.1. RNAi Therapeutics and Technology Market in Europe for Oncological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
33.3.2. RNAi Therapeutics and Technology Market in Europe for Genetic Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
33.3.3. RNAi Therapeutics and Technology Market in Europe for Metabolic Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
33.3.4. RNAi Therapeutics and Technology Market in Europe for Hematological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
33.3.5. RNAi Therapeutics and Technology Market in Europe for Ophthalmic Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
33.3.6. RNAi Therapeutics and Technology Market in Europe for Other Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

33.4. RNAi Technology Market in Europe: Distribution by Type of Payment
33.4.1. RNAi Technology Market in Europe for Upfront Payments, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
33.4.2. RNAi Therapeutics and Technology Market in Europe for Milestone Payments, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

33.5. RNAi Therapeutics and Technology Market in Europe: Distribution by End User
33.5.1. RNAi Therapeutics and Technology Market in Europe for Pharmaceutical and Biotechnology Companies, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
33.5.2. RNAi Therapeutics and Technology Market in Europe for Academic and Research Institutes, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
33.5.3. RNAi Therapeutics and Technology Market in Europe for Contract Development and Manufacturing Organizations, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
33.5.4. RNAi Therapeutics and Technology Market in Europe for Diagnostic Laboratories, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
33.5.5. RNAi Therapeutics and Technology Market in Europe for Other End Users, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

34. RNAi THERAPEUTICS AND TECHNOLOGY MARKET: ASIA-PACIFIC
34.1. RNAi Therapeutics and Technology Market in Asia-Pacific: Distribution by Type of RNAi Molecule
34.1.1. RNAi Therapeutics and Technology Market in Asia-Pacific for siRNA, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
34.1.2. RNAi Therapeutics and Technology Market in Asia-Pacific for miRNA, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
34.1.3. RNAi Therapeutics and Technology Market in Asia-Pacific for shRNA, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
34.1.4. RNAi Therapeutics and Technology Market in Asia-Pacific for Other RNAi Molecules, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

34.2. RNAi Therapeutics and Technology Market in Asia-Pacific: Distribution by Delivery Technology
34.2.1. RNAi Therapeutics and Technology Market in Asia-Pacific for Lipid Nanoparticles, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
34.2.2. RNAi Therapeutics and Technology Market in Asia-Pacific for Emerging Nanomaterials, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
34.2.3. RNAi Therapeutics and Technology Market in Asia-Pacific for Polymer and Conjugate Systems, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
34.2.4. RNAi Therapeutics and Technology Market in Asia-Pacific for Viral Vectors, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
34.2.5. RNAi Therapeutics and Technology Market in Asia-Pacific for Other Delivery Technologies, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

34.3. RNAi Therapeutics and Technology Market in Asia-Pacific: Distribution by Therapeutic Area
34.3.1. RNAi Therapeutics and Technology Market in Asia-Pacific for Oncological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
34.3.2. RNAi Therapeutics and Technology Market in Asia-Pacific for Genetic Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
34.3.3. RNAi Therapeutics and Technology Market in Asia-Pacific for Metabolic Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
34.3.4. RNAi Therapeutics and Technology Market in Asia-Pacific for Hematological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
34.3.5. RNAi Therapeutics and Technology Market in Asia-Pacific for Ophthalmic Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
34.3.6. RNAi Therapeutics and Technology Market in Asia-Pacific for Other Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

34.4. RNAi Technology Market in Asia-Pacific: Distribution by Type of Payment
34.4.1. RNAi Technology Market in Asia-Pacific for Upfront Payments, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
34.4.2. RNAi Technology Market in Asia-Pacific for Milestone Payments, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

34.5. RNAi Therapeutics and Technology Market in Asia-Pacific: Distribution by End User
34.5.1. RNAi Therapeutics and Technology Market in Asia-Pacific for Pharmaceutical and Biotechnology Companies, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
34.5.2. RNAi Therapeutics and Technology Market in Asia-Pacific for Academic and Research Institutes, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
34.5.3. RNAi Therapeutics and Technology Market in Asia-Pacific for Contract Development and Manufacturing Organizations, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
34.5.4. RNAi Therapeutics and Technology Market in Asia-Pacific for Diagnostic Laboratories, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
34.5.5. RNAi Therapeutics and Technology Market in Asia-Pacific for Other End Users, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

35. RNAi THERAPEUTICS AND TECHNOLOGY MARKET: LATIN AMERICA
35.1. RNAi Therapeutics and Technology Market in Latin America: Distribution by Type of RNAi Molecule
35.1.1. RNAi Therapeutics and Technology Market in Latin America for siRNA, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
35.1.2. RNAi Therapeutics and Technology Market in Latin America for miRNA, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
35.1.3. RNAi Therapeutics and Technology Market in Latin America for shRNA, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
35.1.4. RNAi Therapeutics and Technology Market in Latin America for Other RNAi Molecules, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

35.2. RNAi Therapeutics and Technology Market in Latin America: Distribution by Delivery Technology
35.2.1. RNAi Therapeutics and Technology Market in Latin America for Lipid Nanoparticles, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
35.2.2. RNAi Therapeutics and Technology Market in Latin America for Emerging Nanomaterials, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
35.2.3. RNAi Therapeutics and Technology Market in Latin America for Polymer and Conjugate Systems, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

35.2.4. RNAi Therapeutics and Technology Market in Latin America for Viral Vectors, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
35.2.5. RNAi Therapeutics and Technology Market in Latin America for Other Delivery Technologies, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

35.3. RNAi Therapeutics and Technology Market in Latin America: Distribution by Therapeutic Area
35.3.1. RNAi Therapeutics and Technology Market in Latin America for Oncological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
35.3.2. RNAi Therapeutics and Technology Market in Latin America for Genetic Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
35.3.3. RNAi Therapeutics and Technology Market in Latin America for Metabolic Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
35.3.4. RNAi Therapeutics and Technology Market in Latin America for Hematological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
35.3.5. RNAi Therapeutics and Technology Market in Latin America for Ophthalmic Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
35.3.6. RNAi Therapeutics and Technology Market in Latin America for Other Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

35.4. RNAi Technology Market in Latin America: Distribution by Type of Payment
35.4.1. RNAi Technology Market in Latin America for Upfront Payments, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
35.4.2. RNAi Technology Market in Latin America for Milestone Payments, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

35.5. RNAi Therapeutics and Technology Market in Latin America: Distribution by End User
35.5.1. RNAi Therapeutics and Technology Market in Latin America for Pharmaceutical and Biotechnology Companies, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
35.5.2. RNAi Therapeutics and Technology Market in Latin America for Academic and Research Institutes, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
35.5.3. RNAi Therapeutics and Technology Market in Latin America for Contract Development and Manufacturing Organizations, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
35.5.4. RNAi Therapeutics and Technology Market in Latin America for Diagnostic Laboratories, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
35.5.5. RNAi Therapeutics and Technology Market in Latin America for Other End Users, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

36. RNAi THERAPEUTICS AND TECHNOLOGY MARKET: MIDDLE EAST AND NORTH AFRICA
36.1. RNAi Therapeutics and Technology Market in Middle East and North Africa: Distribution by Type of RNAi Molecule
36.1.1. RNAi Therapeutics and Technology Market in Middle East and North Africa for siRNA, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
36.1.2. RNAi Therapeutics and Technology Market in Middle East and North Africa for miRNA, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
36.1.3. RNAi Therapeutics and Technology Market in Middle East and North Africa for shRNA, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
36.1.4. RNAi Therapeutics and Technology Market in Middle East and North Africa for Other RNAi Molecules, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

36.2. RNAi Therapeutics and Technology Market in Middle East and North Africa: Distribution by Delivery Technology
36.2.1. RNAi Therapeutics and Technology Market in Middle East and North Africa for Lipid Nanoparticles, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
36.2.2. RNAi Therapeutics and Technology Market in Middle East and North Africa for Emerging Nanomaterials, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
36.2.3. RNAi Therapeutics and Technology Market in Middle East and North Africa for Polymer and Conjugate Systems, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
36.2.4. RNAi Therapeutics and Technology Market in Middle East and North Africa for Viral Vectors, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
36.2.5. RNAi Therapeutics and Technology Market in Middle East and North Africa for Other Delivery Technologies, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

36.3. RNAi Therapeutics and Technology Market in Middle East and North Africa: Distribution by Therapeutic Area
36.3.1. RNAi Therapeutics and Technology Market in Middle East and North Africa for Oncological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
36.3.2. RNAi Therapeutics and Technology Market in Middle East and North Africa for Genetic Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
36.3.3. RNAi Therapeutics and Technology Market in Middle East and North Africa for Metabolic Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
36.3.4. RNAi Therapeutics and Technology Market in Middle East and North Africa for Hematological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
36.3.5. RNAi Therapeutics and Technology Market in Middle East and North Africa for Ophthalmic Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
36.3.6. RNAi Therapeutics and Technology Market in Middle East and North Africa for Other Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

36.4. RNAi Technology Market in Middle East and North Africa: Distribution by Type of Payment
36.4.1. RNAi Technology Market in Middle East and North Africa for Upfront Payments, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
36.4.2. RNAi Therapeutics and Technology Market in Middle East and North Africa for Milestone Payments, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

36.5. RNAi Therapeutics and Technology Market in Middle East and North Africa: Distribution by End User
36.5.1. RNAi Therapeutics and Technology Market in Middle East and North Africa for Pharmaceutical and Biotechnology Companies, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
36.5.2. RNAi Therapeutics and Technology Market in Middle East and North Africa for Academic and Research Institutes, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
36.5.3. RNAi Therapeutics and Technology Market in Middle East and North Africa for Contract Development and Manufacturing Organizations, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
36.5.4. RNAi Therapeutics and Technology Market in Middle East and North Africa for Diagnostic Laboratories, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
36.5.5. RNAi Therapeutics and Technology Market in Middle East and North Africa for Other End Users, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)

**Detailed information on Chapters 32 to 36 is available in the Excel Data Packs shared along with the report**

37. SWOT ANALYSIS
37.1. Chapter Overview
37.2. Strengths
37.3. Weaknesses
37.4. Opportunities
37.5. Threats

37.6. Comparison of SWOT Factors
37.6.1. Concluding Remarks

38. EXECUTIVE INSIGHTS
38.1. Chapter Overview
38.2. Company A
38.2.1. Company Snapshot
38.2.2. Interview Transcript: Founder and Chief Executive Officer

38.3. Company B
38.3.1. Company Snapshot
38.3.2. Interview Transcript: President and Chief Executive Officer

38.4. Company C
38.4.1. Company Snapshot
38.4.2. Interview Transcript: President and Chief Executive Officer

38.5. Company D
38.5.1. Company Snapshot
38.5.2. Interview Transcript: Chief Executive Officer and Co-Founder

38.6. Company E
38.6.1. Company Snapshot
38.6.2. Interview Transcript: Chief Executive Officer

38.7. Company F
38.7.1. Company Snapshot
38.7.2. Interview Transcript: Senior Vice President, Head of International Region

38.8. Company G
38.8.1. Company Snapshot
38.8.2. Interview Transcript: Executive Vice President, Chief Commercial Officer

38.9. Company H
38.9.1. Company Snapshot
38.9.2. Interview Transcript: Chief Technology Officer and Head of US Operations

38.10. Company I
38.10.1. Company Snapshot
38.10.2. Interview Transcript: Former Chief Medical Officer

38.11. Company J
38.11.1. Company Snapshot
38.11.2. Interview Transcript: Head of Advanced Drug Delivery

39. CONCLUSION
39.1. Chapter Overview
39.2. Key Takeaways

40. APPENDIX 1: TABULATED DATA

41. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 5.1 Executive Summary: Market Landscape
Figure 5.2 Executive Summary: Competitive Landscape
Figure 5.3 Executive Summary: Technology Platforms and Delivery Systems
Figure 5.4 Executive Summary: Clinical Trial Analysis
Figure 5.5 Executive Summary: Patent Analysis
Figure 5.6 Executive Summary: Publication Analysis
Figure 5.7 Executive Summary: Partnerships and Collaborations
Figure 5.8 Executive Summary: Funding and Investment Analysis
Figure 5.9 Executive Summary: Demand Analysis
Figure 5.10 Executive Summary: Market Sizing and Opportunity Analysis
Figure 6.1 RNA Interference: Key Milestones and Historical Evolution
Figure 6.2 RNA Interference: Key Components
Figure 6.3 RNA Interference: Working Mechanism
Figure 6.4 RNA Interference: Types of Delivery Systems
Figure 6.5 RNA Interference: Advantages and Disadvantages
Figure 7.1 RNAi Therapeutics: Distribution by Type of RNAi Molecule
Figure 7.2 RNAi Therapeutics: Distribution by Phase of Development
Figure 7.3 RNAi Therapeutics: Distribution by Molecule and Phase of Development
Figure 7.4 RNAi Therapeutics Pipeline: Distribution by Target Gene
Figure 7.5 RNAi Therapeutics Pipeline: Distribution by Therapeutic Area
Figure 7.6 RNAi Therapeutics Pipeline: Distribution by Route of Administration
Figure 7.7 RNAi Therapeutics: Distribution by Special Drug Designation
Figure 7.8 RNAi Therapeutics: Distribution by Special Drug Designation and Therapeutic Area
Figure 7.9 RNAi Therapeutics: Key Players
Figure 8.1 RNAi Therapeutics Developers: Distribution by Year of Establishment
Figure 8.2 RNAi Therapeutics Developers: Distribution by Company Size
Figure 8.3 RNAi Therapeutics Developers: Distribution by Location of Headquarters
Figure 8.4 RNAi Therapeutics Developers: Distribution by Location of Headquarters (Country)
Figure 8.5 RNAi Therapeutics Developers: Key Players
Figure 8.6 RNAi Therapeutics Developers: Regional Landscape
Figure 9.1 Company Competitiveness Analysis: Developers based in North America
Figure 9.2 Company Competitiveness Analysis: Developers based in Europe
Figure 9.3 Company Competitiveness Analysis: Developers based in Asia-Pacific
Figure 10.1 Onpattro (Alnylam Pharmaceuticals): Timeline of Regulatory Approvals Across Regions
Figure 10.2 Lipid Nanoparticles Delivery System: Mode of Action
Figure 10.3 Givlaari (Alnylam Pharmaceuticals): Timeline of Regulatory Approvals Across Regions
Figure 10.4 ESC-GalNAc Delivery System: Mode of Action
Figure 10.5 Leqvio (Alnylam Pharmaceuticals): Timeline of Regulatory Approvals Across Regions
Figure 11.1 RNAi Technology Platforms: Distribution by Purpose of Technology
Figure 11.2 RNAi Technology Platforms: Distribution by Type of Molecule(s) Delivered
Figure 11.3 RNAi Technology Platforms: Distribution by Type of Cells / Tissues Targeted
Figure 11.4 RNAi Technology Developers: Distribution by Year of Establishment
Figure 11.5 RNAi Technology Developers: Distribution by Company Size
Figure 11.6 RNAi Technology Developers: Distribution by Location of Headquarters (Region)
Figure 11.7 RNAi Technology Developers: Distribution by Location of Headquarters (Country)
Figure 11.8 Protein Nanoparticle Delivery System: Technology Components and Its Assembly
Figure 11.9 mRNAi GOLD Platform: Advantages
Figure 12.1 Technology Competitiveness Analysis: Drug Delivery Technologies
Figure 12.2 Technology Competitiveness Analysis: Drug Discovery / Development Technologies
Figure 13.1 RNAi Therapeutics for Oncological Disorders: Distribution by Target Indication and Phase of Development
Figure 13.2 RNAi Therapeutics for Oncological Disorders: Distribution by Type of RNAi Molecule
Figure 13.3 RNAi Therapeutics for Infectious Diseases: Distribution by Target Indication and Phase of Development
Figure 13.4 RNAi Therapeutics for Infectious Diseases: Distribution by Type of RNAi Molecule
Figure 13.5 RNAi Therapeutics for Metabolic Disorders: Distribution by Target Indication and Phase of Development
Figure 13.6 RNAi Therapeutics for Metabolic Disorders: Distribution by Type of RNAi Molecule
Figure 13.7 RNAi Therapeutics for Ophthalmic Diseases: Distribution by Target Indication and Phase of Development
Figure 13.8 RNAi Therapeutics for Ophthalmic Diseases: Distribution by Type of RNAi Molecule
Figure 13.9 RNAi Therapeutics for Genetic Disorders: Distribution by Target Indication and Phase of Development
Figure 13.10 RNAi Therapeutics for Genetic Disorders: Distribution by Type of RNAi Molecule
Figure 14.1 Clinical Trial Analysis: Methodology
Figure 14.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Since 2014
Figure 14.3 Clinical Trial Analysis: Distribution of Trials by Start Year and Type of Molecule, Since 2014
Figure 14.4 Clinical Trial Analysis: Cumulative Distribution of Enrolled Patient Population by Study Start Year, Since 2014
Figure 14.5 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 14.6 Clinical Trial Analysis: Distribution by Trial Recruitment Status and Phase of Development
Figure 14.7 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 14.8 Clinical Trial Analysis: Distribution by Type of RNAi Molecule and Trial Recruitment Status
Figure 14.9 Clinical Trial Analysis: Distribution by Type of RNAi Molecule and Trial Registration Year
Figure 14.10 Clinical Trial Analysis: Distribution by Type of RNAi Molecule and Phase of Development
Figure 14.11 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 14.12 Clinical Trial Analysis: Distribution by Therapeutic Area and Phase of Development
Figure 14.13 Clinical Trial Analysis: Geographical Distribution of Clinical Trials
Figure 14.14 Clinical Trial Analysis: Geographical Distribution of Clinical Trials by Trial Phase and Recruitment Status
Figure 14.15 Clinical Trial Analysis: Geographical Distribution of Clinical Trials by Type of RNAi Molecule
Figure 14.16 Clinical Trial Analysis: Geographical Distribution of Clinical Trials by Trial Phase and Type of RNAi Molecule
Figure 14.17 Clinical Trial Analysis: Geographical Distribution of Clinical Trials by Trial Phase and Therapeutic Area
Figure 14.18 Clinical Trial Analysis: Geographical Distribution of Clinical Trials by Trial Phase and Therapeutic Area
Figure 14.19 Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population
Figure 14.20 Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population by Trial Phase and Recruitment Status
Figure 14.21 Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population by Type of RNAi Molecule
Figure 14.22 Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population by Trial Phase and Type of RNAi Molecule
Figure 14.23 Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population by Therapeutic Area
Figure 14.24 Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population by Trial Phase and Therapeutic Area
Figure 15.1 KOL Analysis: Distribution by Type of Organization
Figure 15.2 KOL Analysis: Distribution by Qualification
Figure 15.3 KOL Analysis: Distribution by Geographical Location
Figure 15.4 Most Prominent Organizations: Distribution by Number of KOLs
Figure 15.5 Scatter Plot: KOL Activeness v/s KOL Strength
Figure 15.6 Most Prominent KOLs: Distribution by KOL Strength
Figure 15.7 Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Figure 15.8 Linear Regression Analysis: Comparison of RA Score with Third-Party Score
Figure 15.9 Most Prominent KOLs: KOL Activeness v/s KOL Strength
Figure 16.1 Patent Analysis: Distribution by Type of Patent
Figure 16.2 Patent Analysis: Cumulative Distribution by Publication Year, Since 2016
Figure 16.3 Patent Analysis: Distribution by Patent Type and Publication Year
Figure 16.4 Patent Analysis: Distribution by CPC Symbols
Figure 16.5 Patent Analysis: Distribution by Type of Applicant
Figure 16.6 Patent Analysis: Distribution by Geography
Figure 16.7 Patent Analysis: North American Scenario
Figure 16.8 Patent Analysis: European Scenario
Figure 16.9 Patent Analysis: Asia-Pacific Scenario
Figure 16.10 Patent Analysis: Emerging Focus Areas
Figure 16.11 Leading Players (Industry): Distribution by Number of Patents
Figure 16.12 Leading Players (Non-Industry): Distribution by Number of Patents
Figure 16.13 Patent Analysis: Benchmarking by Patent Characteristics
Figure 16.14 Patent Analysis (Leading Industry Players): Benchmarking by Patent Characteristics
Figure 16.15 Patent Analysis: Distribution by Patent Age, Since 2016
Figure 16.16 Patent Analysis: Categorizations based on Weighted Valuation Scores
Figure 16.17 Patent Analysis: Patent Valuation
Figure 17.1 Publication Analysis: Cumulative Year-wise Trend, Since 2016
Figure 17.2 Publication Analysis: Distribution by Type of Publication
Figure 17.3 Publication Analysis: Most Popular Keywords
Figure 17.4 Most Popular Journals: Distribution by Number of Publications
Figure 17.5 Most Popular Publishers: Distribution by Number of Publications
Figure 17.6 Most Popular Copyright Holders: Distribution by Number of Publications
Figure 17.7 Key Funding Institutes: Distribution by Number of Publications
Figure 18.1 Partnerships: Cumulative Year-Wise Trend, Since 2014
Figure 18.2 Partnerships: Distribution by Type of Partnership
Figure 18.3 Partnerships: Year-wise Trend by Type of Partnership
Figure 18.4 Partnerships: Distribution by Type of RNAi Molecule
Figure 18.5 Partnerships: Distribution by Scale of Partnership
Figure 18.6 Partnerships: Distribution by Therapeutic Area
Figure 18.7 Most Active Players: Distribution by Number of Partnerships
Figure 18.8 Partnerships: Local and International Agreements
Figure 18.9 Partnerships: Intercontinental and Intracontinental Distribution
Figure 19.1 Funding and Investment Analysis: Distribution by Type of Funding and Year of Establishment, Since 2014
Figure 19.2 Funding and Investment Analysis: Cumulative Number of Instances by Year, Since 2014
Figure 19.3 Funding and Investment Analysis: Cumulative Amount Invested, Since 2014 (USD Million)
Figure 19.4 Funding and Investment Analysis: Distribution by Year, Type of Funding and Amount Invested, Since 2014
Figure 19.5 Funding and Investment Analysis: Distribution of Instances by Type of Funding, Since 2014
Figure 19.6 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Funding, Since 2014 (USD Million)
Figure 19.7 Funding and Investments: Distribution of Number of Instances by Year and Type of Funding
Figure 19.8 Funding and Investments: Distribution by Amount Invested across Different Types of RNAi Therapeutics
Figure 19.9 Funding and Investment Analysis: Distribution by Geography
Figure 19.10 Funding and Investment Analysis: Regional Distribution of Funding Instances
Figure 19.11 Most Active Players: Distribution by Number of Instances, Since 2014
Figure 19.12 Most Active Players: Distribution by Amount Invested, Since 2014 (USD Million)
Figure 19.13 Key Investors: Distribution by Number of Instances
Figure 19.14 Funding and Investment Summary, Since 2014 (USD Million)
Figure 20.1 Successful Drug Launch Strategy: ROOTS Framework
Figure 20.2 Successful Drug Launch Strategy: Product Differentiation
Figure 20.3 Commonly Adopted Commercialization Strategies based on Development Stage of the Product
Figure 20.4 Harvey Ball Analysis: Commercialization Strategies Adopted by RNAi-Based Therapy Developers
Figure 20.5 Approved RNAi Therapies: Snapshot of Promotional Activities on Product Websites
Figure 20.6 Key Commercialization Strategies: Harvey Ball Analysis by Ease of Implementation, Value Addition and Current Adoption
Figure 21.1 Circulating miRNA Biomarkers: Key Criteria
Figure 21.2 Factors Determining Useful Cancer Screening
Figure 21.3 Conventional Methods for Cancer Diagnosis
Figure 22.1 RNAi Therapeutics: Types of Service Providers
Figure 22.2 RNAi Therapeutic CROs: Distribution by Year of Establishment
Figure 22.3 RNAi Therapeutics CROs: Distribution by Location of Headquarters
Figure 22.4 RNAi Therapeutics CROs: Distribution by Company Size
Figure 22.5 RNAi Therapeutics CMOs: Distribution by Year of Establishment
Figure 22.6 RNAi Therapeutics CMOs: Distribution by Location of Headquarters
Figure 22.7 RNAi Therapeutics CMOs: Distribution by Company Size
Figure 22.8 RNAi Therapeutic Consumable Providers: Distribution by Year of Establishment
Figure 22.9 RNAi Therapeutic Consumable Providers: Distribution by Location of Headquarters
Figure 22.10 RNAi Therapeutic Consumable Providers: Distribution by Company Size
Figure 23.1 Global Demand for RNAi Therapeutics, till 2035 (in terms of Target Patient Population)
Figure 23.2 Demand Analysis: Distribution by Type of Molecule (in terms of Target Patient Population)
Figure 23.3 Demand Analysis: Distribution by Therapeutic Area (in terms of Target Patient Population)
Figure 23.4 Demand Analysis: Distribution by Route of Administration (in terms of Target Patient Population)
Figure 23.5 Demand Analysis: Distribution by Key Players (in terms of Target Patient Population)
Figure 23.6 Demand Analysis: Distribution by Geography (in terms of Target Patient Population)
Figure 24.1 Global RNAi Therapeutics and Technology Market, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Figure 24.2 Global RNAi Therapeutics and Technology Market, Forecasted Estimates (Till 2035), Conservative Scenario (USD Million)
Figure 24.3 Global RNAi Therapeutics and Technology Market, Forecasted Estimates (Till 2035), Optimistic Scenario (USD Million)
Figure 25.1 RNAi Therapeutics and Technology Market: Distribution by Type of RNAi Molecule
Figure 25.2 RNAi Therapeutics and Technology Market for siRNA, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Figure 25.3 RNAi Therapeutics and Technology Market for miRNA, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Figure 25.4 RNAi Therapeutics and Technology Market for shRNA, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Figure 25.5 RNAi Therapeutics and Technology Market for Other RNAi Molecules, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Figure 26.1 RNAi Therapeutics and Technology Market: Distribution by Delivery Technology
Figure 26.2 RNAi Therapeutics and Technology Market for Lipid Nanoparticles, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Figure 26.3 RNAi Therapeutics and Technology Market for Emerging Nanomaterials, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Figure 26.4 RNAi Therapeutics and Technology Market for Polymer and Conjugate Systems, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Figure 26.5 RNAi Therapeutics and Technology Market for Viral Vectors, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Figure 26.6 RNAi Therapeutics and Technology Market for Other Delivery Technologies, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Figure 27.1 RNAi Therapeutics and Technology Market: Distribution by Therapeutic Area
Figure 27.2 RNAi Therapeutics and Technology Market for Oncological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Figure 27.3 RNAi Therapeutics and Technology Market for Genetic Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Figure 27.4 RNAi Therapeutics and Technology Market for Metabolic Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Figure 27.5 RNAi Therapeutics and Technology Market for Hematological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Figure 27.6 RNAi Therapeutics and Technology Market for Ophthalmic Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Figure 27.7 RNAi Therapeutics and Technology Market for Other Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Figure 28.1 RNAi Technology Market: Distribution by Type of Payment
Figure 28.2 RNAi Technology Market for Upfront Payments, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Figure 28.3 RNAi Technology Market for Milestone Payments, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Figure 29.1 RNAi Therapeutics and Technology Market: Distribution by End User
Figure 29.2 RNAi Therapeutics and Technology Market for Pharmaceutical and Biotechnology Companies, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Figure 29.3 RNAi Therapeutics and Technology Market for Academic and Research Institutes, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Figure 29.4 RNAi Therapeutics and Technology Market for Contract Development and Manufacturing Organizations, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Figure 29.5 RNAi Therapeutics and Technology Market for Diagnostic Laboratories, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Figure 29.6 RNAi Therapeutics and Technology Market for Other End Users, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.1 RNAi Therapeutics and Technology Market: Distribution by Geographical Regions
Figure 30.2 RNAi Therapeutics and Technology Market in North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.3 RNAi Therapeutics and Technology Market in Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.4 RNAi Therapeutics and Technology Market in Asia-Pacific, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.5 RNAi Therapeutics and Technology Market in Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.6 RNAi Therapeutics and Technology Market in Middle East and North Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.7 RNAi Therapeutics and Technology Market: Revenue Shift Analysis
Figure 30.8 RNAi Therapeutics and Technology Market: Penetration Growth (P-G) Matrix
Figure 37.1 RNAi Therapeutics and Technology Market: SWOT Analysis
Figure 37.2 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 39.1 Concluding Remarks: Market Overview
Figure 39.2 Concluding Remarks: Competitive Landscape
Figure 39.3 Concluding Remarks: Company Competitiveness Analysis
Figure 39.4 Concluding Remarks: Technology Platforms and Delivery Systems
Figure 39.5 Concluding Remarks: Technology Competitiveness Analysis
Figure 39.6 Concluding Remarks: Clinical Trial Analysis
Figure 39.7 Concluding Remarks: Key Opinion Leaders
Figure 39.8 Concluding Remarks: Patent Analysis
Figure 39.9 Concluding Remarks: Publication Analysis
Figure 39.10 Concluding Remarks: Recent Partnerships
Figure 39.11 Concluding Remarks: Funding and Investment Analysis
Figure 39.12 Concluding Remarks: Key Commercialization Strategies
Figure 39.13 Concluding Remarks: Demand Analysis
Figure 39.14 Concluding Remarks: Market Forecast and Opportunity Analysis (1/2)
Figure 39.15 Concluding Remarks: Market Forecast and Opportunity Analysis (2/2)

List of Tables

Table 6.1 Merits and Demerits of RNAi Delivery Systems
Table 6.2 Comparison between siRNA, miRNA and shRNA
Table 7.1 RNAi Therapeutics: Marketed and Development Pipeline
Table 7.2 RNAi Therapeutics: Information on Special Drug Designation
Table 8.1 RNAi Therapeutics: List of Developers
Table 10.1 RNAi Therapeutics: List of Marketed and Approved Products
Table 10.2 Onpattro® (Patisiran): Drug Overview
Table 10.3 Onpattro® (Patisiran): Information on Completed and Active Clinical Trials
Table 10.4 Givlaari® (ALN-AS1): Drug Overview
Table 10.5 Givlaari®: Information on Completed and Active Clinical Trials
Table 10.6 Leqvio® (Inclisiran): Drug Overview
Table 10.7 Leqvio® (Inclisiran): Information on Completed and Active Clinical Trials
Table 10.8 Oxlumo® (Lumasiran): Drug Overview
Table 10.9 Oxlumo® (Lumasiran): Information on Completed and Active Clinical Trials
Table 10.10 Qfitlia™ (ALN-AT3): Drug Overview
Table 10.11 Qfitlia™ (ALN-AT3): Information on Completed and Active Clinical Trials
Table 10.12 Amvuttra® (ALN-TTRsc02): Drug Overview
Table 10.13 Amvuttra® (ALN-TTRsc02): Information on Completed and Active Clinical Trials
Table 10.14 SYL1001(Tivanisiran): Drug Overview
Table 10.15 SYL1001(Tivanisiran): Information on Completed and Active Clinical Trials
Table 10.16 Vigil-EWS: Drug Overview
Table 10.17 Vigil-EWS: Information on Completed and Active Clinical Trials
Table 10.18 Rivfloza™: Drug Overview
Table 10.19 Rivfloza™: Completed and Active Clinical Trials
Table 11.1 Self-deliverable RNA molecules
Table 11.2 List of RNAi Technology / Platforms
Table 11.3 List of RNAi Technology Developers
Table 11.4 ESC-GalNAc: Pipeline Molecules
Table 11.5 Protein Nanoparticle Delivery Technology: Pipeline Molecules
Table 11.6 TRiM: Pipeline Molecules
Table 11.7 GalXC: Pipeline Molecules
Table 11.8 Vigil: Pipeline Molecules
Table 11.9 mRNAi GOLD Platform: Pipeline Molecules
Table 14.1 Clinical Trial Analysis: Key Therapeutic Candidates
Table 14.2 Clinical Trial Analysis: Key Clinical Trials
Table 15.1 Key Opinion Leaders: List of Principal Investigators Involved in Clinical Trials
Table 16.1 Patent Analysis: CPC Code Definitions
Table 16.2 Patent Analysis: Most Popular CPC Codes
Table 16.3 Patent Analysis: List of Top CPC Codes
Table 16.4 Patent Analysis: Summary of Benchmarking Analysis
Table 16.5 Patent Analysis: List of Leading Patents (by Highest Relative Valuation)
Table 17.1 RNAi Therapeutics: List of Publications
Table 18.1 RNAi Therapeutics: List of Partnerships, Since 2014
Table 19.1 RNAi Therapeutics: List of Funding and Investments, Since 2014
Table 19.2 Funding and Investment Analysis: Summary of Investments
Table 20.1 Onpattro®: Presentations in Conferences Before Product Approval
Table 20.2 Givlaari®: Presentations in Conferences Before Product Approval
Table 20.3 Oxlumo®: Presentations in Conferences Before Product Approval
Table 20.4 Onpattro®: Presentations in Conferences After Product Approval
Table 20.5 Leqvio®: Presentations in Conferences Before Product Approval
Table 20.6 Approved RNAi Therapies: Patient Support Services Available on Product Websites (Comparative Analysis)
Table 20.7 Leqvio®: Presentations in Conferences After Product Approval
Table 20.8 Approved RNAi Therapies: Patient Support Services Available on Product Websites (Comparative Analysis)
Table 21.1 Survival on Early Diagnosis of Cancer
Table 21.2 Cost of Biopsy for Different Cancer Indications (in USD)
Table 21.3 Breast Cancer: Reported miRNA Biomarkers
Table 21.4 Colorectal Cancer: Reported miRNA Biomarkers
Table 21.5 Gastric Cancer: Reported miRNA Biomarkers
Table 21.6 AML: Reported miRNA Biomarkers
Table 21.7 de novo DLBCL: Reported miRNA Biomarkers
Table 21.8 Lung Cancer: Reported miRNA Biomarkers
Table 21.9 Prostate Cancer: Reported miRNA Biomarkers
Table 21.10 Coronary Artery Disease: Reported miRNA Biomarkers
Table 21.11 Myocardial Infarction: Reported miRNA Biomarkers
Table 21.12 miRNA Diagnostic Tests: Pipeline
Table 22.1 RNAi Therapeutics: List of CROs
Table 22.2 RNAi Therapeutics: List of CMOs
Table 22.3 RNAi Therapeutics: List of Consumables Providers and Other Service Providers
Table 37.1 RNAi Therapeutics: SWOT Analysis
Table 37.2 Comparison of SWOT Factors: Harvey Ball Analysis
Table 39.1 Concluding Remarks: Market Overview
Table 39.2 Concluding Remarks: Competitive Landscape
Table 39.3 Concluding Remarks: Company Competitiveness Analysis
Table 39.4 Concluding Remarks: Technology Competitiveness Analysis
Table 39.5 Concluding Remarks: Clinical Trial Analysis
Table 39.6 Concluding Remarks: Key Opinion Leaders
Table 39.7 Concluding Remarks: Patent Analysis
Table 39.8 Concluding Remarks: Publication Analysis
Table 39.9 Concluding Remarks: Recent Partnerships
Table 39.10 Concluding Remarks: Funding and Investment Analysis
Table 39.11 Concluding Remarks: Demand Analysis
Table 39.12 Concluding Remarks: Market Sizing and Opportunity Analysis
Table 40.1 RNAi Therapeutics: Distribution by Type of RNAi Molecule
Table 40.2 RNAi Therapeutics: Distribution by Phase of Development
Table 40.3 RNAi Therapeutics: Distribution by Type of RNAi Molecule and Phase of Development
Table 40.4 RNAi Therapeutics: Distribution by Target Gene
Table 40.5 RNAi Therapeutics: Distribution by Therapeutic Area
Table 40.6 RNAi Therapeutics: Distribution by Route of Administration
Table 40.7 RNAi Therapeutics: Distribution by Special Drug Designation
Table 40.8 RNAi Therapeutics: Distribution by Special Drug Designation and Therapeutic Area
Table 40.9 RNAi Therapeutics: Key Players
Table 40.10 RNAi Therapeutics Developers: Distribution by Year of Establishment
Table 40.11 RNAi Therapeutics Developers: Distribution by Company Size
Table 40.12 RNAi Therapeutics Developers: Distribution by Location of Headquarters (Region)
Table 40.13 RNAi Therapeutics Developers: Distribution by Location of Headquarters (Country)
Table 40.14 RNAi Therapeutics Developers: Key Players
Table 40.15 RNAi Technology Platforms: Distribution by Purpose of Technology
Table 40.16 RNAi Technology Platforms: Distribution by Type of Molecule(s) Delivered
Table 40.17 RNAi Technology Platforms: Distribution by Type of Cell/ Tissue Targeted
Table 40.18 RNAi Technology Developers: Distribution by Year of Establishment
Table 40.19 RNAi Technology Developers: Distribution by Company Size
Table 40.20 RNAi Technology Developers: Distribution by Location of Headquarters (Region)
Table 40.21 RNAi Technology Developers: Distribution by Location of Headquarters (Country)
Table 40.22 RNAi Therapeutics for Oncological Disorders: Distribution by Target Indication and Phase of Development
Table 40.23 RNAi Therapeutics for Oncological Disorders: Distribution by Type of RNAi Molecule
Table 40.24 RNAi Therapeutics for Infectious Diseases: Distribution by Target Indication and Phase of Development
Table 40.25 RNAi Therapeutics for Infectious Diseases: Distribution by Type of RNAi Molecule
Table 40.26 RNAi Therapeutics for Metabolic Disorders: Distribution by Target Indication and Phase of Development
Table 40.27 RNAi Therapeutics for Metabolic Disorders: Distribution by Type of RNAi Molecule
Table 40.28 RNAi Therapeutics for Ophthalmic Diseases: Distribution by Target Indication and Phase of Development
Table 40.29 RNAi Therapeutics for Ophthalmic Diseases: Distribution by Type of RNAi Molecule
Table 40.30 RNAi Therapeutics for Genetic Disorders: Distribution by Target Indication and Phase of Development
Table 40.31 RNAi Therapeutics for Genetic Disorders: Distribution by Type of RNAi Molecule
Table 40.32 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Since 2014
Table 40.33 Clinical Trial Analysis: Distribution of Trials by Start Year and Type of Molecule, Since 2014
Table 40.34 Cumulative Distribution of Enrolled Patient Population by Study Start Year, Since 2014
Table 40.35 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Table 40.36 Clinical Trial Analysis: Distribution by Trial Recruitment Status and Phase of Development
Table 40.37 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 40.38 Clinical Trial Analysis: Distribution by Type of RNAi Molecule and Trial Recruitment Status
Table 40.39 Clinical Trial Analysis: Distribution by Type of RNAi Molecule and Trial Registration Year
Table 40.40 Clinical Trial Analysis: Distribution by Type of RNAi Molecule and Phase of Development
Table 40.41 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 40.42 Clinical Trial Analysis: Distribution by Therapeutic Area and Phase of Development
Table 40.43 Clinical Trial Analysis: Geographical Distribution of Clinical Trials
Table 40.44 Clinical Trial Analysis: Geographical Distribution of Clinical Trials by Trial Phase and Recruitment Status
Table 40.45 Clinical Trial Analysis: Geographical Distribution of Clinical Trials by Type of RNAi Molecule
Table 40.46 Clinical Trial Analysis: Geographical Distribution of Clinical Trials by Trial Phase and Type of RNAi Molecule
Table 40.47 Clinical Trial Analysis: Geographical Distribution of Clinical Trials by Trial Phase and Therapeutic Area
Table 40.48 Geographical Analysis by Number of Clinical Trials, Therapeutic Area and Trial Phase
Table 40.49 Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population
Table 40.50 Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population by Trial Phase and Recruitment Status
Table 40.51 Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population by Type of RNAi Molecule
Table 40.52 Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population by Trial Phase and Type of RNAi Molecule
Table 40.53 Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population by Therapeutic Area
Table 40.54 Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population by Trial Phase and Therapeutic Area
Table 40.55 Key Opinion Leaders: Distribution by Type of Organization
Table 40.56 KOL Analysis: Distribution by Qualification
Table 40.57 KOL Analysis: Distribution by Geographical Location
Table 40.58 Most Prominent Organizations: Distribution by Number of KOLs
Table 40.59 Most Prominent KOLs: Distribution by KOL Strength
Table 40.60 Patent Analysis: Distribution by Type of Patent
Table 40.61 Patent Analysis: Cumulative Distribution by Publication Year, Since 2016
Table 40.62 Patent Analysis: Distribution by Patent Type and Publication Year
Table 40.63 Patent Analysis: Distribution by Type of Applicant
Table 40.64 Patent Analysis: Distribution by Geography
Table 40.65 Patent Analysis: North American Scenario
Table 40.66 Patent Analysis: European Scenario
Table 40.67 Patent Analysis: Asia-Pacific Scenario
Table 40.68 Leading Players (Industry): Distribution by Number of Patents
Table 40.69 Leading Players (Non-Industry): Distribution by Number of Patents
Table 40.70 Patent Analysis: Distribution by Patent Age, Since 2016
Table 40.71 Publication Analysis: Cumulative Year-wise Trend, Since 2016
Table 40.72 Publication Analysis: Distribution by Type of Publication
Table 40.73 Publication Analysis: Most Popular Keywords
Table 40.74 Top Journals: Distribution by Number of Publications
Table 40.75 Top Publishers: Distribution by Number of Publications
Table 40.76 Key Copyright Holders: Distribution by Number of Publications
Table 40.77 Key Funding Institutes: Distribution by Number of Publications
Table 40.78 Partnerships: Cumulative Year-Wise Trend, Since 2014
Table 40.79 Partnerships: Distribution by Type of Partnership
Table 40.80 Partnerships: Year-wise Trend by Type of Partnership
Table 40.81 Partnerships: Distribution by Type of RNAi Molecule
Table 40.82 Partnerships: Distribution by Scale of Partnership
Table 40.83 Partnerships: Distribution by Therapeutic Area
Table 40.84 Most Active Players: Distribution by Number of Partnerships
Table 40.85 Partnerships: Local and International Agreements
Table 40.86 Partnerships: Intercontinental and Intracontinental Distribution
Table 40.87 Funding and Investment Analysis: Distribution by Type of Funding and Year of Establishment, Since 2014
Table 40.88 Funding and Investment Analysis: Cumulative Number of Instances by Year, Since 2014
Table 40.89 Funding and Investment Analysis: Cumulative Amount Invested, Since 2014 (USD Million)
Table 40.90 Funding and Investment Analysis: Distribution of Instances by Type of Funding, Since 2014
Table 40.91 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Funding, Since 2014 (USD Million)
Table 40.92 Funding and Investments: Distribution of Number of Instances by Year and Type of Funding
Table 40.93 Funding and Investments: Distribution of Amount Invested across Different Types of RNAi Therapeutics
Table 40.94 Funding and Investment Analysis: Distribution by Geography
Table 40.95 Funding and Investment Analysis: Regional Distribution of Funding Instances
Table 40.96 Most Active Players: Distribution by Number of Instances, Since 2014
Table 40.97 Most Active Players: Distribution by Amount Invested, Since 2014 (USD Million)
Table 40.98 Key Investors: Distribution by Number of Instances
Table 40.99 RNAi Therapeutics: Types of Service Providers
Table 40.100 RNAi Therapeutic CROs: Distribution by Year of Establishment
Table 40.101 RNAi Therapeutics CROs: Distribution by Location of Headquarters
Table 40.102 RNAi Therapeutics CROs: Distribution by Company Size
Table 40.103 RNAi Therapeutics CROs: Distribution by Type of RNAi Molecule
Table 40.104 RNAi Therapeutics CMOs: Distribution by Year of Establishment
Table 40.105 RNAi Therapeutics CMOs: Distribution by Location of Headquarters
Table 40.106 RNAi Therapeutics CMOs: Distribution by Company Size
Table 40.107 RNAi Therapeutic Consumable Providers: Distribution by Year of Establishment
Table 40.108 RNAi Therapeutic Consumable Providers: Distribution by Location of Headquarters
Table 40.109 RNAi Therapeutic Consumable Providers: Distribution by Company Size
Table 40.110 RNAi Therapeutic Consumable Providers: Distribution by Type of RNAi Molecule
Table 40.111 Global Demand for RNAi Therapeutics, till 2035 (in terms of Target Patient Population)
Table 40.112 Demand Analysis: Distribution by Type of Molecule (in terms of Target Patient Population)
Table 40.113 Demand Analysis: Distribution by Therapeutic Area (in terms of Target Patient Population)
Table 40.114 Demand Analysis: Distribution by Route of Administration (in terms of Target Patient Population)
Table 40.115 Demand Analysis: Distribution by Key Players (in terms of Target Patient Population)
Table 40.116 Demand Analysis: Distribution by Geography (in terms of Target Patient Population)
Table 40.117 Global RNAi Therapeutics and Technology Market, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Table 40.118 Global RNAi Therapeutics and Technology Market, Forecasted Estimates (Till 2035), Conservative Scenario (USD Million)
Table 40.119 Global RNAi Therapeutics and Technology Market, Forecasted Estimates (Till 2035), Optimistic Scenario (USD Million)
Table 40.120 RNAi Therapeutics and Technology Market: Distribution by Type of RNAi Molecule
Table 40.121 RNAi Therapeutics and Technology Market for siRNA, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Table 40.122 RNAi Therapeutics and Technology Market for miRNA, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Table 40.123 RNAi Therapeutics and Technology Market for shRNA, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Table 40.124 RNAi Therapeutics and Technology Market for Other RNAi Molecules, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Table 40.125 RNAi Therapeutics and Technology Market: Distribution by Delivery Technology
Table 40.126 RNAi Therapeutics and Technology Market for Lipid Nanoparticles, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Table 40.127 RNAi Therapeutics and Technology Market for Emerging Nanomaterials, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Table 40.128 RNAi Therapeutics and Technology Market for Polymer and Conjugate Systems, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Table 40.129 RNAi Therapeutics and Technology Market for Viral Vectors, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Table 40.130 RNAi Therapeutics and Technology Market for Other Delivery Technologies, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Table 40.131 RNAi Therapeutics and Technology Market: Distribution by Therapeutic Area
Table 40.132 RNAi Therapeutics and Technology Market for Oncological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Table 40.133 RNAi Therapeutics and Technology Market for Genetic Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Table 40.134 RNAi Therapeutics and Technology Market for Metabolic Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Table 40.135 RNAi Therapeutics and Technology Market for Hematological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Table 40.136 RNAi Therapeutics and Technology Market for Ophthalmic Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Table 40.137 RNAi Therapeutics and Technology Market for Other Disorders, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Table 40.138 RNAi Technology Market: Distribution by Type of Payment
Table 40.139 RNAi Therapeutics and Technology Market for Upfront Payments, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Table 40.140 RNAi Therapeutics and Technology Market for Milestone Payments, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Table 40.141 RNAi Therapeutics and Technology Market: Distribution by End User
Table 40.142 RNAi Therapeutics and Technology Market for Pharmaceutical and Biotechnology Companies, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Table 40.143 RNAi Therapeutics and Technology Market for Academic and Research Institutes, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Table 40.144 RNAi Therapeutics and Technology Market for Contract Development and Manufacturing Organizations, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Table 40.145 RNAi Therapeutics and Technology Market for Diagnostic Laboratories, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Table 40.146 RNAi Therapeutics and Technology Market for Other End Users, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Table 40.147 RNAi Therapeutics and Technology Market: Distribution by Geographical Regions
Table 40.148 RNAi Therapeutics and Technology Market in North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Table 40.149 RNAi Therapeutics and Technology Market in Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Table 40.150 RNAi Therapeutics and Technology Market in Asia-Pacific, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Table 40.151 RNAi Therapeutics and Technology Market in Latin America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Table 40.152 RNAi Therapeutics and Technology Market in Middle East and North Africa, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035) (USD Million)
Table 40.153 RNAi Therapeutics and Technology Market: Revenue Shift Analysis
Table 40.154 RNAi Therapeutics and Technology Market: Penetration Growth (P-G) Matrix